Damian Hiley | Managing Director, Vaccine Division
Desert King

Day 1 - Tuesday 14th October @ 16:00

Panel: Adjuvants: Optimizing Strategies for Emerging Pathogens and Equitable Access

Strategies to overcome IP and licensing barriers to increase global availability of key adjuvant systems. 

What is the optimal modular approach to selecting the right adjuvant for a target antigen, especially during pandemic speed? 

Balancing cost, risk, and benefit to ensure a continuous supply of excipients during outbreaks. 

Exploring the regulatory and economic potential of aligning human and minmal vaccine infrastructures to reduce production costs

Damian Hiley, Managing Director, Vaccine Division, Desert King

×

Damian Hiley / Panel: Adjuvants: Optimizing Strategies for Emerging Pathogens and Equitable Access

Damian Hiley, Managing Director, Vaccine Division,
Desert King

Damian Hiley is Managing Director – Vaccine Division at Desert King International, where he has overseen the development and global supply of GMP-grade QS-21 and related saponin adjuvants. Desert King’s adjuvants are currently used in five licensed vaccines worldwide, with additional candidates in...

CloseMore

Shannon Miller, VP Operations, Inimmune Corporation

Dennis Christensen, Head of Global R&D, Croda Pharma

×

Dennis Christensen / Panel: Adjuvants: Optimizing Strategies for Emerging Pathogens and Equitable Access

Dennis Christensen, Head of Global R&D,
Croda Pharma

Dr. Christensen was recently appointed as Global Head of R&D for Adjuvant Systems at Croda Pharma after 18 years in adjuvant research at Statens Serum Institut, Denmark. During his career, his research focus has been on pharmaceutical and immunological aspects of vaccine adjuvants and delivery...

CloseMore

Roland Ventura, VFI Advisor, Vaccine Formulation Institute

×

Roland Ventura / Panel: Adjuvants: Optimizing Strategies for Emerging Pathogens and Equitable Access

Roland Ventura, VFI Advisor,
Vaccine Formulation Institute

Roland Ventura holds a PhD in molecular biology and vaccines from the Queen’s University Belfast.  After postdoctoral training at the University of Oxford he worked with Dako A/S in Denmark under a European Commission-funded Marie Curie Transfer of Knowledge Fellowship.  Following this, he became...

CloseMore

Daniel Fullen, Research and Development Innovations Lead, CEPI

×

Daniel Fullen / Panel: Adjuvants: Optimizing Strategies for Emerging Pathogens and Equitable Access

Daniel Fullen, Research and Development Innovations Lead,
CEPI

Daniel Fullen is a seasoned professional in the field of vaccine research and development, currently serving as the Research and Development Innovations Lead at the Coalition for Epidemic Preparedness Innovations (CEPI) and leads CEPI's adjuvant programme. With a strong background in immunology ...

CloseMore

Moderator: Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine

×

Maria Elena Bottazzi / Panel: Adjuvants: Optimizing Strategies for Emerging Pathogens and Equitable Access

Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development,
Baylor College of Medicine

Dr. Maria Elena Bottazzi is an internationally recognized tropical and emerging disease vaccinologist, global health advocate and cocreator of a patent-free, open science COVID-19 vaccine technology that led to the development of Corbevax in India and IndoVac in Indonesia, and with approximately...

CloseMore

Day 3 - Thursday 16th October @ 10:00

The Gold Standard QS-21 for Vaccine Adjuvants - Delivered by Desert King

Session led by:

×

Damian Hiley / The Gold Standard QS-21 for Vaccine Adjuvants - Delivered by Desert King

Damian Hiley, Managing Director, Vaccine Division,
Desert King

Damian Hiley is Managing Director – Vaccine Division at Desert King International, where he has overseen the development and global supply of GMP-grade QS-21 and related saponin adjuvants. Desert King’s adjuvants are currently used in five licensed vaccines worldwide, with additional candidates in...

CloseMore

Zoltan Beck, Science advisor, Desert King

×

Zoltan Beck / The Gold Standard QS-21 for Vaccine Adjuvants - Delivered by Desert King

Zoltan Beck, Science advisor,
Desert King

Zoltan Beck is a scientific advisor with deep expertise in vaccine innovation, adjuvant systems, and formulation R&D, driven by a passion for translating complex science into practical solutions that advance human health. Over the past decades, he has led and contributed to adjuvant and vaccine ...

CloseMore